Kajal Aggarwal's wedding with Gautam Kitchlu has been the talk of the town for quite some time now. After creating a lot of buzz about their love affair and wedding, the actress has finally tied the knot with her man.
Kajal Aggarwal's wedding with Gautam Kitchlu has been the talk of the town for quite some time now. After creating a lot of buzz about their love affair and wedding, the actress has finally tied the knot with her man.
British finance minister Rishi Sunak, who has already pledged over 200 billion pounds to fight the COVID-19 crisis, will free up more cash on Wednesday against the backdrop of the heaviest public borrowing since World War Two. Sunak will announce extra investment to ease a backlog in the health system, counter a surge in unemployment and build new infrastructure in a one-year Spending Review that he is due to deliver to parliament at around 1230 GMT. With Britain's full exit from the European Union approaching on Dec. 31 - and no new trade agreement yet secured - Sunak is likely to announce more spending on customs operations and possibly replacement subsidies for farmers.
Lancome deals for Black Friday 2020, featuring perfume, skin & face serum & more savings
Wilmington (Delaware) [US], November 25 (ANI): Introducing the top members of his security and foreign policy team, US President-elect Joe Biden on Tuesday called it a team that reflects his belief that "America is strongest when it works with its allies".
Welsh commissioner offers funding to help staff leave abusive relationships. Pioneering scheme will provide grants or loans to help pay for relocation or essential supplies
Study into dementia risks from heading seeks female players to volunteer
UK housing market expects 100,000 extra home sales in early 2021. Property rebound predicted to continue as buyers rush to complete before stamp duty holiday ends
National curriculum ‘systematically omits' black British history. The Black Curriculum report says England’s ‘white, Eurocentric curriculum’ fails to reflect UK society
Domestic abuse victims with 'trapped capital' should not be denied legal aid, court rules. Decision is victory for victims who have homes which cannot be sold or borrowed against
CALGARY, Alberta, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Cardinal Energy Ltd. ("Cardinal") (TSX: CJ) Cardinal is pleased to announce it has agreed to a term sheet reflecting extensive discussions with certain existing and new lenders that would provide Cardinal with longer term certainty around its credit facility. These terms are still awaiting formal approvals from the involved parties which are expected to be received by December 15, 2020. Based on the term sheet, the credit facility is expected to be renewed for $225 million with current market terms for a conforming reserve based lending facility. With strengthening commodity prices, the Company continues to add to its 2021 hedge position to lock-in pricing at attractive levels.Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements and forward-looking information (collectively "forward-looking statements") within the meaning of applicable securities laws relating to Cardinal's plans and other aspects of Cardinal's anticipated future operations. Forward looking information typically uses words such as "anticipate", "believe", "project", "expect", "goal", "plan", "intend", "may", "would", "could" or "will" or similar words suggesting future outcomes, events or performance. The forward-looking statements contained in this press release speak only as of the date hereof and are expressly qualified by this cautionary statement.Specifically, and without limiting the generality of the foregoing, all statements included in this press release that address activities, events or developments that Cardinal expects or anticipates will or may occur in the future, including, but not limited to statements with respect to the amended terms of Cardinal's credit facility and that the terms will be agreed to by December 15, 2020, constitute forward-looking statements under applicable Canadian securities laws and necessarily involve known and unknown risks and uncertainties, most of which are beyond Cardinal's control including, without limitation: the risk that the credit facility will not be amended on the anticipated terms or at all.Management has included the forward-looking statements above and a summary of assumptions and risks related to forward looking statements provided in this press release in order to provide readers with a more complete perspective on Cardinal's future operations and such information may not be appropriate for other purposes. Cardinal's actual results, performance or achievement could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits that Cardinal will derive there from. Readers are cautioned that the foregoing lists of factors are not exhaustive. These forward-looking statements are made as of the date of this press release and Cardinal disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. About Cardinal Energy Ltd. One of Cardinal's goals is to continually improve our Environmental, Safety and Governance mandate and operate our assets in a responsible and environmentally sensitive manner. As part of this mandate, Cardinal injects and conserves more carbon than it directly emits making us one of the few Canadian energy companies to have a negative carbon footprint.Cardinal is a Canadian oil focused company with operations focused on low decline light and medium quality oil in Western Canada.For further information: M. Scott Ratushny, CEO or Shawn Van Spankeren, CFO or Laurence Broos, VP Finance Email: email@example.com Phone: (403) 234-8681 Website: www.cardinalenergy.ca
The government's shared ownership scheme has left some with rising fees and huge debts, BBC Panorama finds.
When Sami Wunder started out as a dating and relationships coach there was one issue that scared her.
Tom Brady and the Tampa Bay Buccaneers are searching for answers for their inconsistency.
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and October 1, 2020, inclusive (the “Class Period”), of the important December 7, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Mesoblast investors under the federal securities laws. To join the Mesoblast class action, go to http://www.rosenlegal.com/cases-register-1923.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action.According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast’s Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory acute graft versus host disease (“aGVHD”) due to design differences between the four studies; (2) as a result, the U.S. Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, defendants’ positive statements about Mesoblast’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1923.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.\-------------------------------Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 firstname.lastname@example.org email@example.com firstname.lastname@example.org www.rosenlegal.com
DALLAS, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Primoris Services Corporation (NASDAQ Global Select: PRIM) (“Primoris” or “Company”) today announced that its senior management will be participating in the Credit Suisse 8th Annual Virtual Industrials Conference on Wednesday, December 2, 2020. A copy of the Company’s presentation will be made available for download the morning of the conference. Please visit the Investor Relations section of Primoris’ website at www.prim.com. Once at the Investor Relations section, please select “Events & Presentations”.ABOUT PRIMORIS Founded in 1960, Primoris, through various subsidiaries, has grown to become one of the leading providers of specialty contracting services operating mainly in the United States and Canada. Primoris provides a wide range of specialty construction services, fabrication, maintenance, replacement, and engineering services to a diversified base of customers. The Company’s national footprint extends from Florida, along the Gulf Coast, through California, into the Pacific Northwest and into Canada. For additional information, please visit www.prim.com.Company Contact: Brook Wootton Vice President, Investor Relations email@example.com
Recently Published Report on “Glass Manufacturing Market Size, Share, Growth, Trends, Consumption, Production, Segment Forecasts, Regional Outlook 2020 - 2027”. OTTAWA, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The global glass manufacturing market was valued at US$ 129.2 billion in 2019 and expected to reach US$ 180.94 billion by 2027, with at a compound annual growth rate (CAGR) of 4.3% during the forecast period 2020 to 2027.Glass manufacturing is basically a fabrication method for producing fiber glass, container glass, flat glass, and specialty glass. The manufacturing technology is largely dependent on the product type. For instance, float glass process is mainly used in manufacturing of flat glass whereas container glasses are produced through blowing process.Glass has transformed from luxurious decorative piece to a functional material with numerous advancements in different industry verticals. Glasses are a versatile material and witness wide scale of application ranging from construction to aeronautics industry.Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1125Growth FactorsRising construction activities along with the government initiatives supporting development of infrastructural are accentuating the glass manufacturing market over the projected period. For instance, in December 2019, 16 mega projects for construction sector were announced catering to the commercial and hospitality segments in UAE that provides significant growth potential for the glass industry in the developing and developed economies.Regional SnapshotsThe Asia Pacific witnessed as affront-runner in the global glass manufacturing market accounting for nearly 50% of the total volume share in the year 2019. The remarkable share of the region is mainly due to continuous shift in R&D facilities and production units of various manufacturing sectors in the region. Significant number of manufacturers is shifting towards the Asia Pacific because of the availability of economical land, labor, and raw materials.In addition, rising awareness among consumers for the usage of glass materials in place of plastics materials projected to augment the market size of glass manufacturing in the region. Besides this, the region is an attractive center for various manufacturers owing to low price of raw materials, low labor cost, and low cost of manufacturing process that collectively accounts for high profit margin as the overall cost of operation decreases.View Full Report with Complete Report ToC@ https://www.precedenceresearch.com/glass-manufacturing-marketEurope experiences strong domestic demand for container glasses that expected to spur the rate of production in the region. As per the European Union, nearly 80% of the manufactured glasses in the region are traded domestically within the European countries. Container glass is the most consumed glass among others due to rise in beer and alcohol industry. The European Commission has stated that container glasses alone contribute more than 55% of total glass output in the region. Further, countries including Germany and France have strong presence of aerospace and automotive industries that again contribute for the increasing demand for specialty glasses in the region.Report Highlights * Asia Pacific encountered was the prime market with nearly 50% of the volume stake in 2019 attributed to the significant presence of consumer base for numerous applications of glass * North America emerged as the third largest market in terms of volume in the year 2019 owing to significant demand for glass materials in packaging sector * Europe experiences strong demand for container glasses because of flourishing growth of beer industry as well as significant rise in the alcohol consumption in the region * Container glass captured the maximum market share in terms of volume accounting for around 50% in 2019 due to the rapid growth of beer industry along with significant demand of alcoholic beverages * Fiberglass estimated to show the fastest growth rate over 4% between during assessment period due to extensive application of fiberglass in automobile industry * Packaging application dominated the global market and accounted for a value share of roughly 45% in 2019 owing to its superior flavor retention capability * Electronics application projected to register the fastest growth of over 5.0% in terms of value over the forecast timeframe attributed to the rapid expansion and rising innovation in the production of consumer electronic devices Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1125Key Players & StrategiesGlobal glass manufacturing market is highly competitive owing to prominent market players adopting mergers &acquisition strategy to uplift their market share. For instance, in May 2017, Nippon Electric Glass acquired PPG’s fiberglass to expand and explore fiberglass business in automotive and aeronautics business areas. Similarly, in March 2017, Vitro signed an agreement to acquire PGW to enhance its existence in North American market.Industry players also invest notable in the research &development (R&D) sector to gain competitive edge in the global market in terms of technology. In September 2017, Saint Gobain launched its new thermal insulation glazing flat glass product. The product aimed at its application in residential and commercial segment by providing unprecedented thermal insulation and higher transparency.Some of the key players operating in the market are AGC Inc., Heinz Glass, Nippon Sheet Glass Co., Ltd., Saint Gobain, Central Glass Co. Ltd., Nippon Electric Glass Co. Ltd., Guardian Industries, Fuyao Glass Industry Group Co., Ltd., Owens Illinois Inc., NSG Co., Ltd, Koa Glass, Nihon Yamamura, Amcor, and 3B - the fiberglass company among others.Market SegmentationBy Product * Flat Glass * Container Glass * Fiberglass * OthersBy Application * Construction * Packaging * Transportation * Telecommunication * Electronics * OthersBy Regional Outlook * North America * U.S. * Canada * Europe * U.K. * Germany * France * Asia Pacific * China * India * Japan * South Korea * Rest of the World Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1125You can place an order or ask any questions, please feel free to contact at firstname.lastname@example.org | +1 774 402 6168About UsPrecedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.For Latest Update Follow Us:https://www.linkedin.com/company/precedence-research/
The Fuel Oil Market will grow by USD 84.77 bn during 2020-2024
DENVER, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announced that management will participate in the following investor conferences in December 2020: * Diamond Equity Research Emerging Growth Invitational on December 1, 2020. Assure’s executive chairman and CEO John Farlinger is scheduled to present on December 1st at 1:00 p.m. ET. Register for the webcast here: https://us02web.zoom.us/webinar/register/WN_KuHurFdvRh2Y_jOQJe8sYg * Lytham Partners Virtual Investor Growth Conference on December 7-11, 2020. Management will be participating in virtual one-on-one meetings with institutional investors. To arrange a meeting, please contact Lytham Partners at email@example.com or visit www.lythampartners.com/virtual.About Assure Holdings Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commission’s Gold Seal of Approval®. For more information, visit the company’s website at www.assureneuromonitoring.com.Forward-Looking Statements This news release may contain “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company’s operations and economic activity in general, and risks and uncertainties discussed in our most recent annual and quarterly reports filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Contact Scott Kozak, Investor and Media Relations Assure Holdings Corp. 1-720-287-3093 Scott.Kozak@assureiom.com
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Eastern District of Michigan on behalf of investors that purchased Credit Acceptance Corporation (NASDAQ: CACC) common stock between November 1, 2019 and August 28, 2020 (the “Class Period”). Investors have until December 1, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action.Credit Acceptance provides financing programs, and related products and services to independent and franchised automobile dealers in the United States. These programs are offered through a nationwide network of automobile dealers who benefit from sales of vehicles to consumers who otherwise could not obtain financing, as 95% of Credit Acceptance’s loans are considered subprime. The Company’s tag line is “We change lives!” and the Company asserts its financing programs give consumers “a second chance” in improving their credit scores.The ugly truth about the Company’s predatory and illegal business practices was revealed on August 28, 2020 when the Massachusetts Attorney General filed the Mass AG Complaint against Credit Acceptance alleging that Credit Acceptance has, for years, been making unfair and deceptive automobile loans to thousands of Massachusetts consumers. In addition, the lawsuit specifically alleges that Credit Acceptance provided its investors with false and/or misleading information regarding the asset-backed securitizations they offered to investors, and that the Company engaged in unfair debt collection practices as well.In response to the public disclosure of the Mass AG Complaint, Credit Acceptance’s stock price fell $85.36 per share, or over 18%, to close at $374.07 per share over two trading days ending on September 1, 2020.The complaint, filed on October 2, 2020, alleges that defendants failed to disclose to investors: (i) that the Company was topping off the pools of loans that they packaged and securitized with higher-risk loans; (ii) that Credit Acceptance was making high interest subprime auto loans to borrowers that the Company knew borrowers would be unable to repay; (iii) that the borrowers were subject to hidden finance charges, resulting in loans exceeding the usury rate ceiling mandated by state law; (iv) that Credit Acceptance took excessive and illegal measures to collect debt from defaulted borrowers; (v) that, as a result, the Company was likely to face regulatory scrutiny and possible penalties from various regulators or lawsuits; and (vi) that, as a result of the foregoing, defendants positive statements about the Company’s business, operations, and adherence to appropriate laws and regulations were materially misleading and/or lacked a reasonable basis.If you purchased Credit Acceptance common stock during the Class Period and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at firstname.lastname@example.org, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. Marion Passmore, Esq. (212) 355-4648 email@example.com www.bespc.com
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Celsion Corporation (NASDAQ: CLSN), Citigroup, Inc. (NYSE: C), Raytheon Technologies Corporation (NYSE: RTX), and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Celsion Corporation (NASDAQ: CLSN) Class Period: November 2, 2015 to July 10, 2020Lead Plaintiff Deadline: December 28, 2020Celsion is an integrated development clinical stage oncology drug company that focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer.Celsion’s lead product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin that is in Phase III clinical development for treating primary liver cancer.In February 2014, Celsion announced that the U.S. Food and Drug Administration (“FDA”) had reviewed and provided clearance for the Company’s planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox in combination with radio frequency ablation (“RFA”) in primary liver cancer, also known as hepatocellular carcinoma (“HCC”), called the “OPTIMA Study.” The trial design was purportedly based on a comprehensive analysis of data from the Company’s Phase III HEAT Study, which purportedly demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival (“OS”) in a substantial number of HCC patients that received an optimized RFA treatment. On July 13, 2020, Celsion announced that “it ha[d] received a recommendation from the independent [DMC] to consider stopping the global Phase III OPTIMA Study of ThermoDox® in combination with [RFA] for the treatment of [HCC], or primary liver cancer.” According to the Company, “[t]he recommendation was made following the second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020,” which “found that the pre-specified boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903.”On this news, Celsion’s stock price fell $2.29 per share, or 63.97%, to close at $1.29 per share on July 13, 2020.The complaint, filed on October 29, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) defendants had significantly overstated the efficacy of ThermoDox; (ii) the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.For more information on the Celsion class action go to: https://bespc.com/cases/CLSNCitigroup, Inc. (NYSE: C) Class Period: January 15, 2016 to October 12, 2020Lead Plaintiff Deadline: December 29, 2020The Class Period begins on February 25, 2017, following the Company’s submission of its 2016 Annual Report to the SEC. In that filing, and throughout the Class Period, Citi assured investors that there were no significant deficiencies or material weaknesses in the Company’s internal controls. When faced with periodic regulatory penalties for noncompliance, the Company continued to assure investors that the specific deficiencies at issue were being remediated promptly and that internal controls and regulatory compliance were a top priority at Citi. In particular, Citi assured investors that it satisfied all regulatory requirements and maintained adequate internal controls, data governance, compliance risk management, and enterprise risk management.In reality, during the Class Period and unbeknownst to investors, Citi’s internal controls and risk management capabilities suffered from “serious” and “longstanding” inadequacies that exposed the Company to massive regulatory penalties and will cost significantly more than $1 billion to remediate. Specific control failures about which Citi executives were warned remained unresolved for years and the Company’s culture of non-compliance was so widespread that Citi’s CEO, Defendant Michael Corbat, exhorted employees in an internal memo that regulatory compliance required more than “checking boxes.”The truth began to emerge on September 14, 2020, when reports surfaced that regulators were preparing to reprimand Citi for failing to improve its risk-management systems.That disclosure caused the price of Citi’s stock to decline $2.85 per share, from $51.00 to $48.15, erasing $5.91 billion in shareholder value.After the market closed on September 14, 2020, an internal memo sent to Citi employees revealed for the first time the Company’s disregard for adequate internal controls and regulatory compliance.As a result, the price of Citi’s stock declined an additional $3.34 per share, from $48.15 to $44.81, erasing $6.93 billion in shareholder value.Then, on October 13, 2020, Citi reported earnings for the third quarter of 2020, and disclosed that the Company’s expenses increased during the third quarter by 5%, to $11 billion, due to an increase in costs including a $400 million fine, investments in infrastructure, and other remediation costs related to control deficiencies.These disclosures caused Citi’s stock price to decline by $2.20 per share, from $45.88 to $43.68, erasing $4.57 billion in shareholder value.For more information on the Citigroup class action go to: https://bespc.com/cases/CRaytheon Technologies Corporation (NYSE: RTX) Class Period: February 10, 2016 to October 27, 2020Lead Plaintiff Deadline: December 29, 2020On October 27, 2020, after market hours, Raytheon filed its quarterly report on Form 10-Q with the SEC for the quarter ended September 30, 2020 (the “3Q20 Report”). The 3Q20 Report announced the DOJ Investigation, stating in pertinent part: “On October 8, 2020, the Company received a criminal subpoena from the DOJ seeking information and documents in connection with an investigation relating to financial accounting, internal controls over financial reporting, and cost reporting regarding Raytheon Company’s Missiles & Defense business since 2009.”On this news, the price of Raytheon shares fell $4.19 per share, or 7%, to close at $52.34 per share on October 28, 2020, on unusually heavy trading volume, damaging investors.The complaint, filed on October 30, 2020, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Raytheon had inadequate disclosure controls and procedures and internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon's Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice (“DOJ”); and (6) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.For more information on the Raytheon class action go to: https://bespc.com/cases/RTXIntercept Pharmaceuticals, Inc. (NASDAQ: ICPT) Class Period: September 28, 2019 to October 7, 2020Lead Plaintiff Deadline: January 4, 2021Intercept’s lead product candidate is Ocaliva (obeticholic acid (“OCA”)), a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (“PBC”), a rare and chronic liver disease, in combination with ursodeoxycholic acid in adults. The Company is also developing OCA for various other indications, including nonalcoholic steatohepatitis (“NASH”).On May 22, 2020, Intercept reported that the FDA “has notified Intercept that its tentatively scheduled June 9, 2020 advisory committee meeting (AdCom) relating to the company’s [NDA] for [OCA] for the treatment of liver fibrosis due to [NASH] has been postponed” to “accommodate the review of additional data requested by the FDA that the company intends to submit within the next week.”On this news, Intercept’s stock price fell $11.18 per share, or 12.19%, to close at $80.51 per share on May 22, 2020.On June 29, 2020, Intercept issued a press release announcing that the FDA had issued a Complete Response Letter (“CRL”) rejecting the Company’s NDA for Ocaliva for the treatment of liver fibrosis due to NASH.On this news, Intercept’s stock price fell $30.79 per share, or 39.73%, to close at $46.70 per share on June 29, 2020.Then, on October 8, 2020, news outlets reported that Intercept was “facing an investigation from the [FDA] over the potential risk of liver injury in patients taking Ocaliva, [Intercept’s] treatment for primary biliary cholangitis, a rare, chronic liver disease.”On this news, Intercept’s stock price fell $3.30 per share, or 8.05%, to close at $37.69 per share on October 8, 2020.The complaint, filed on November 5, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s use in treating PBC; (ii) the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA’s efficacy in treating NASH were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company’s NDA for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.For more information on the Intercept class action go to: https://bespc.com/cases/ICPT-2About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. Marion Passmore, Esq. (212) 355-4648 firstname.lastname@example.org www.bespc.com
Save on Shoe Carnival deals at the Black Friday sale, including the top snow boots, winter boots, shoes & more offers Compare the latest Shoe Carnival deals for Black Friday 2020, including all the latest shoes, sneakers, boots and more offers. Links to the best deals are listed below. Best Shoe Carnival Deals: * Save up to 33% on a wide range of Nike shoes, sneakers & accessories at ShoeCarnival.com \- shop the latest Nike collections, including the Nike Air Max, Big Kid & Little Kid sneakers and running shoes * Save up to 25% on adidas sneakers & running shoes at ShoeCarnival.com \- including deals on the adidas Cloudfoam Racer sneakers and Hoop sneakers for men, women & toddlers * Save up to 64% on men’s and women’s boots & booties at ShoeCarnival.com \- find the biggest savings on duck boots, winter boots, hiking boots, work boots, and booties from UGG, Dr. Martens & more * Save up to 50% on men’s shoes from brands like Vans, Nike, Levi’s & more at ShoeCarnival.com \- shop the wide range of men’s boots, oxfords, casual shoes, running shoes, sneakers & more * Save up to 42% on an extensive selection of women’s shoes, slippers & sandals at ShoeCarnival.com \- including the hottest deals on Dr. Martens combat boots, adidas sneakers, Nike running shoes & more * Save up to 20% on kids’ running shoes, sneakers & boots at ShoeCarnival.com \- check the latest deals on footwear for boys and girls Want some more deals? Click here to view the entire selection of active deals at Walmart’s Black Friday sale and click here to shop Amazon’s live Black Friday deals. Consumer Walk earns commissions from purchases made using the links provided.Footwear retail giant Shoe Carnival carries over 200 brands in their digital and physical stores ranging from budget shoe brands to high-end designer labels. Their vast collection of footwear for men, women, and kids of all ages are available to purchase at reasonable prices. Shoppers can find great deals, discounts, and sales. From running shoes, fancy heels, dressy loafers to protective work boots, you’re sure to find something from Shoe Carnival to match your lifestyle. About Consumer Walk: Consumer Walk reports the latest online retail news. As an Amazon Associate and affiliate Consumer Walk earns from qualifying purchases. Contact: Andy Mathews (email@example.com)